Terns Pharmaceuticals, Inc. Common Stock (TERN) Stock Price
TERNStock
$0.00−30.12%52W
Market Cap—
P/E—
PEG Ratio—
Div yield—
Beta-1.20
TERN Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)541.28%
Price vs S&P 500 (4W)-7.06%
VGM Score33.06
TERN Earnings Surprise History
Q1 25-0.26est. -0.27
Q2 25-0.26est. -0.29
Q3 25-0.27est. -0.30
Q4 25-0.24est. -0.28
TERN Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
3.47
3.47
3.47
3.47
Industry Peers — Pharmaceuticals(571)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
TERNTerns Pharmaceuticals, Inc. Common Stock | — | F | B | $0.00 |
| LLYEli Lilly & Co. | D | B | B | $1233.66 |
| JNJJohnson & Johnson | D | C | B | $273.14 |
| ABBVABBVIE INC. | D | C | B | $265.79 |
| MRKMerck & Co., Inc. | D | C | A | $156.45 |
| NVSNovartis AG | C | C | C | $159.98 |
| AZNAstraZeneca PLC | C | B | C | $169.66 |
| NVONovo-Nordisk A/S | B | C | C | $48.66 |
| ABTAbbott Laboratories | C | C | B | $116.13 |
| PFEPfizer Inc. | C | D | C | $28.57 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $552.85 |
About Terns Pharmaceuticals, Inc. Common Stock
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing small-molecule therapies for non-alcoholic steatohepatitis (NASH) and other chronic liver diseases. The company's pipeline includes multiple candidates, including TERN-701, TERN-601, TERN-501, and TERN-800, designed for both single-agent and combination therapy approaches to address significant unmet clinical needs in liver disease treatment.